Crossmark

Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients

Crossref DOI link: https://doi.org/10.1007/s10072-025-08267-8

Published Online: 2025-06-12

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Dan

Sun, Na

Wu, Hongbo

Wang, Xueying

Shi, Yongjing

Yang, Lin

Huang, Shaoping

Zhang, Kun

Yang, Changhong https://orcid.org/0009-0002-5547-4126
Funding

Funding for this research was provided by:

Key R&D Project of Shaanxi Province (2021SF-087)
License Information

Text and Data Mining valid from 2025-06-12

Version of Record valid from 2025-06-12
More Information

Article History

Received: 11 March 2025

Accepted: 21 May 2025

First Online: 12 June 2025

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University (2022 Ethical Approval Study No. 038).

: Informed consent was obtained from all individual participants included in the study.

: Patients signed informed consent regarding publishing their data.

Document is current

Any future updates will be listed below